In Russia, registered the first localized vaccine against meningococcus

Petrovax Pharm has received a registration certificate for a quadrivalent conjugated vaccine against Mentetra meningococcal infection. About the registration of the vaccine was reported in the company, in the state register of medicines, the data has not yet been displayed. The vaccine protects against serogroups of meningococcus A, C, W and Y. The emergence of full-cycle production within the Russian Federation is a key condition for the inclusion of the vaccine in the National Calendar of Preventive Vaccinations.

The Ministry of Health planned to expand the calendar with a meningococcal vaccination before the end of 2025, but as a result, the timing was shifted to 2027. Currently, vaccination is not included in the NCCP: procurement of drugs is carried out at the expense of the budgets of only certain regions or vaccinations are made for epidemic indications.

Investments of Petrovax Pharm in the project to localize production on a full cycle exceeded 3 billion rubles. By the beginning of 2027, the plant’s capacity should be enough to produce more than 6 million doses per year, the company said.

According to Rospotrebnadzor, in 2025 the incidence of meningococcal infection increased 2.7 times year-on-year. 36% of cases are migrant workers from neighboring countries who are not immune to serogroup A strains of meningococcus circulating in Russia.

Other players are also developing and testing their own vaccines against meningococcus in Russia, in particular the St. Petersburg Research Institute of Vaccines and Serums.

Read more about public procurement of vaccines against meningococcus - in the material "Kommersant" "Vaccination was decimated by a virus.".

Victoria Kolganova